跳至主要内容
临床试验/NCT01687985
NCT01687985已完成2 期

A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults

Braintree Laboratories4 个研究点 分布在 1 个国家目标入组 81 人开始时间: 2012年8月最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
81
试验地点
4
主要终点
Treatment Success

研究概览

简要总结

A pilot study to evaluate the safety and efficacy of multiple BLI801 doses in constipated adults.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female subjects at least 18 years of age
  • Constipated, defined by ROME definition:
  • Otherwise in good health, as determined by physical exam and medical history

排除标准

  • Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon
  • Subjects taking laxatives or prokinetic agents that refuse to discontinue these treatments
  • Subjects who are allergic to any BLI801 component
  • Subjects currently taking narcotic analgesics or other medications known to cause constipation
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures
  • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
  • Subjects with an active history of drug or alcohol abuse

研究组 & 干预措施

BLI801 laxative - low dose

Experimental

BLI801 laxative - oral solution

干预措施: BLI801 laxative - low dose (Drug)

BLI801 laxative - high dose

Experimental

BLI801 laxative - oral solution

干预措施: BLI801 laxative - high dose (Drug)

结局指标

主要结局

Treatment Success

时间窗: 4 weeks

percent of patients experiencing a response in 3 out of 4 weeks of treatment

次要结局

  • serum chemistry(4 weeks)

研究者

发起方
Braintree Laboratories
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验